V Square Quantitative Management LLC Acquires Shares of 16,253 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

V Square Quantitative Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the second quarter, Holdings Channel reports. The fund acquired 16,253 shares of the company’s stock, valued at approximately $263,000.

Other hedge funds also recently bought and sold shares of the company. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $30,000. Beach Investment Counsel Inc. PA acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $48,000. Industrial Alliance Investment Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $54,000. Finally, GAMMA Investing LLC increased its holdings in shares of Teva Pharmaceutical Industries by 105.7% in the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after purchasing an additional 1,741 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research reports. Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Wednesday, July 10th. Piper Sandler restated an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Insider Activity

In other news, Director Roberto Mignone sold 519,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the sale, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at $777,285. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.69 during midday trading on Wednesday, hitting $17.82. 11,982,925 shares of the company traded hands, compared to its average volume of 10,369,075. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $18.05. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The business has a 50 day simple moving average of $16.83 and a 200-day simple moving average of $15.03. The stock has a market capitalization of $20.18 billion, a price-to-earnings ratio of -41.79, a price-to-earnings-growth ratio of 1.51 and a beta of 0.90.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.